Qynapse Unveils Strategic Rebrand To Support Accelerated Growth And New Corporate Vision
PR91756
BOSTON, Sept. 20, 2021 /PRNewswire=KYODO JBN/
Qynapse Inc., a medical technology company commercializing an AI-powered
neuroimaging software platform for central nervous system (CNS) disorders,
unveils a full rebrand including new logo and a complete website redesign,
intended to better reflect the company's strategic vision, focus and its
commitment to excellence.
The company has placed patient centricity at the core of its rebranding
strategy, as Qynapse is striving to offer tools and solutions that help
clinicians, payers and pharma get the most out of neuroimaging, with the goal
of improving measurement precision, patient outcomes and quality of life for
CNS diseases.
"Before the inception of Qynapse in 2015, we envisioned a future where
neuroimaging AI was widely accepted and adopted as a critical solution for both
clinical routine and clinical trials. Today, major steps have been achieved
towards that vision. We are excited to launch our new brand identity that
better reflects the organization Qynapse has become, committed to bringing
game-changing technology to serve a brighter and more accurate future of
diagnosis and treatment for patients with brain disorders," said Qynapse CEO,
Olivier Courreges.
Qynapse's extensive rebranding initiative stems from some important milestones
that the company has reached in the past year. Tackling new global markets such
as Asia Pacific while maintaining a strong focus in Europe and North America
has reinforced Qynapse's stance as a neuroscience industry leader.
Qynapse continues to pave the way towards more accurate, more reliable
screening and monitoring of CNS disease in both clinical routine settings and
clinical trial applications. Together, with its world-renowned team of
scientific and clinical partners, Qynapse has developed one of the largest
datasets of proprietary
algorithms providing over 200 measures of neurodegeneration and
neuroinflammation, to rapidly, accurately and objectively analyze and interpret
brain scans.
"As an industry, our thinking has evolved. AI is now a critical partner with
humans to drive impactful change across the healthcare ecosystem. For
healthcare providers, payers, pharma and, above all, patients, we aim to bring
ground-breaking peace of mind by providing results they can trust, and our new
brand identity makes this motivation shine through. It also reflects our
long-term vision, to combine imaging data together with other biomarkers and
patient modalities to positively impact clinical trial outcomes and facilitate
decision making across the CNS care continuum," concluded Matt Ullum, Chief
Commercial Officer at Qynapse.
Visit the new Qynapse website: www.qynapse.com
About Qynapse Inc.:
Qynapse is a medical technology company commercializing an AI-powered and
proprietary neuroimaging software platform that creates the potential for
earlier clinical precision on the frontlines of CNS disease.
Qynapse's flagship solution, QyScore(R), FDA-Cleared and CE-Marked, combines
MRI scans and AI to produce rapid, actionable insights, adding the potential
for more precise and objective brain scan analysis. Qynapse's predictive AI
technology, QyPredict(R), available for research-use-only, has the potential to
predict disease trajectory and improve targeted patient selection in clinical
trials.
Qynapse is headquartered in France, in the US and in Canada.
ysalledechou@qynapse.com
Logo- https://mma.prnewswire.com/media/1628911/QYNAPSE_Logo.jpg
SOURCE: QYNAPSE
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。